Advertisement
GSK vs SNY
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GSK is a Buy and SNY is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
GSK’s FA Score shows that 1 FA rating(s) are green whileSNY’s FA Score has 1 green FA rating(s).
- GSK’s FA Score: 1 green, 4 red.
- SNY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
GSK’s TA Score shows that 6 TA indicator(s) are bullish while SNY’s TA Score has 7 bullish TA indicator(s).
- GSK’s TA Score: 6 bullish, 4 bearish.
- SNY’s TA Score: 7 bullish, 3 bearish.
Price Growth
GSK (@Pharmaceuticals: Major) experienced а -1.60% price change this week, while SNY (@Pharmaceuticals: Major) price change was -1.32% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.84%. For the same industry, the average monthly price growth was +1.29%, and the average quarterly price growth was +11.90%.
Reported Earning Dates
GSK is expected to report earnings on Oct 29, 2025.
SNY is expected to report earnings on Oct 24, 2025.
Industries' Descriptions
@Pharmaceuticals: Major (-1.84% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| GSK | SNY | GSK / SNY | |
| Capitalization | 80.3B | 123B | 65% |
| EBITDA | 8.61B | 12.6B | 68% |
| Gain YTD | 20.573 | 8.134 | 253% |
| P/E Ratio | 17.69 | 16.66 | 106% |
| Revenue | 31.6B | 45.7B | 69% |
| Total Cash | 3.62B | 15.4B | 24% |
| Total Debt | 17.4B | 22.3B | 78% |
GSK | SNY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 23 | 14 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 7 Undervalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 68 | 71 | |
SMR RATING 1..100 | 100 | 100 | |
PRICE GROWTH RATING 1..100 | 53 | 60 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SNY's Valuation (5) in the Pharmaceuticals Major industry is in the same range as GSK (7). This means that SNY’s stock grew similarly to GSK’s over the last 12 months.
GSK's Profit vs Risk Rating (68) in the Pharmaceuticals Major industry is in the same range as SNY (71). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.
GSK's SMR Rating (100) in the Pharmaceuticals Major industry is in the same range as SNY (100). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.
GSK's Price Growth Rating (53) in the Pharmaceuticals Major industry is in the same range as SNY (60). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.
GSK's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as SNY (100). This means that GSK’s stock grew similarly to SNY’s over the last 12 months.
| GSK | SNY | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 49% | 2 days ago 38% |
| Stochastic ODDS (%) | 2 days ago 48% | 2 days ago 51% |
| Momentum ODDS (%) | 2 days ago 54% | 2 days ago 58% |
| MACD ODDS (%) | 2 days ago 52% | 2 days ago 47% |
| TrendWeek ODDS (%) | 2 days ago 52% | 2 days ago 49% |
| TrendMonth ODDS (%) | 2 days ago 53% | 2 days ago 50% |
| Advances ODDS (%) | 3 days ago 58% | 8 days ago 51% |
| Declines ODDS (%) | 24 days ago 54% | 2 days ago 49% |
| BollingerBands ODDS (%) | 2 days ago 48% | 2 days ago 65% |
| Aroon ODDS (%) | 2 days ago 46% | 2 days ago 58% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| RMT | 10.24 | 0.03 | +0.29% |
| Royce Micro-Cap Trust | |||
| VCLT | 76.02 | 0.20 | +0.26% |
| Vanguard Long-Term Corporate Bd ETF | |||
| HYI | 11.89 | 0.01 | +0.08% |
| Western Asset High Yield Opportunity Fund Inc | |||
| MSTQ | 37.09 | N/A | N/A |
| LHA Market State™ Tactical Q ETF | |||
| NDAA | 20.98 | N/A | N/A |
| Ned Davis Research 360 Dyn Allc ETF | |||
GSK and
Correlation & Price change
A.I.dvisor indicates that over the last year, GSK has been closely correlated with NVS. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if GSK jumps, then NVS could also see price increases.
SNY and
Correlation & Price change
A.I.dvisor indicates that over the last year, SNY has been loosely correlated with SNYNF. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if SNY jumps, then SNYNF could also see price increases.